Sun Pharma in partnership with ICGEB to develop dengue vaccine

Sun Pharma has entered into a partnership with International Centre for Genetic Engineering and Biotechnology (ICGEB) to work on dengue vaccine which would be better and affordable than the existing vaccines available in the market.

 

October 20, 2016: Sun Pharma has entered into a partnership with International Centre for Genetic Engineering and Biotechnology (ICGEB) to work on dengue vaccine which would be better and affordable than the existing vaccines available in the market.

 

Sun Pharma would be funding development of the vaccine candidate DSV4 which targets all four variations of the dengue virus. It is expected that DSV4 would take less time for development as compared to others. Preclinical studies for the vaccines have been completed while the toxicology studies on animals would commence soon followed by the clinical trail phase. The exclusive rights and licenses as well as the commercialisation of the vaccine globally would be taken care of by Sun Pharma whereas ICGEB would receive pre-defined royalty and milestone payments. DSV4 is a custom made recombinant virus-like-particle based vaccine which wouldn’t need to use a live attenuated virus in its development.

 

There has been a considerable rise in the incidence of dengue with 51,731 cases being reported and 93 deaths so far in 2016. There has been a greater degree of commitment and attention to work on vaccines and drugs to fight against  flaviviruses which have become of significant  importance in India and the world at large.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...